Vidaza 25 mg/ml powder for suspension for injection clinical trials
6 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment-naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy (VENAZA-5S PILOT TRIAL)
This study looks at a new way to treat acute myeloid leukaemia (AML) in adults who can't have standard treatment. It combines two existing medicines, Venclyxto and Vidaza, to see how well they work together and if they can help patients get better.
For: Acute myeloid leukemiaGermany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment
This study is testing a new drug, S65487, with an existing drug, azacitidine, for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for patients who haven't had treatment before and can't have intensive chemotherapy. We want to check if it's safe and how well it works.
For: Acute Myeloid Leukemia (AML)France · Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukaemia (AML) in adults. We want to see if a drug called gilteritinib, alone or with another drug, helps people live longer compared to standard treatment, especially for those who can't have strong chemotherapy.
For: Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction ChemotherapyGermany · Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label Phase I/II Study of Relatlimab (BMS-986016) with Nivolumab (BMS-936558) in Combination with 5-Azacytidine for Relapsed/Refractory Acute Myeloid Leukemia and in Combination with 5-Azacytidine and Venetoclax for Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Negative for NPM1 and IDH 1/2 Mutations Who Are Ineligible for Intensive Chemotherapy (AARON)
This study looks at new drug combinations for acute myeloid leukaemia (AML). It aims to find the safest dose and see how well these combinations work in people whose AML has come back or not responded to treatment, and in newly diagnosed patients who can't have strong chemotherapy.
For: Acute Myeloid LeukemiaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
This study looks at new treatments for a type of blood cancer called Acute Myeloid Leukemia (AML) in adults who can't have strong chemotherapy. It compares a drug combination of three medicines (pevonedistat, venetoclax, and azacitidine) against a two-drug combination (venetoclax and azacitidine) to see which works best.
For: Acute Myeloid LeukemiaItaly · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial
This study looks at new, personalised treatments for older people with certain blood cancers like Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS). It compares these 'precision' treatments with standard care to see which works best and offers the best value for money in improving quality of life.
For: Chronic myelomonocyte leukemia · Myelodysplastic syndrome · Acute myeloid leukemiaNorway